e-ISSN: Pending
Negative / Null Result ReportOpen accessImmunology and Microbiology· cited by 26

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Dahham Alsoud; Dirk Jan A. R. Moes; Zhigang Wang; Rani Soenen; Zohra Layegh; Murray L. Barclay; Tomoyuki Mizuno; Iris K. Minichmayr · 2024 · Therapeutic Drug Monitoring

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract (excerpt)

BACKGROUND: Infliximab, an anti-tumor necrosis factor monoclonal antibody, has revolutionized the pharmacological management of immune-mediated inflammatory diseases (IMIDs). This position statement critically reviews and examines existing…

Excerpt shown for reference under fair use — read the full paper at the publisher.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1097/ftd.0000000000001204